WO2017194903A3 - Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune - Google Patents

Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune Download PDF

Info

Publication number
WO2017194903A3
WO2017194903A3 PCT/FR2017/051165 FR2017051165W WO2017194903A3 WO 2017194903 A3 WO2017194903 A3 WO 2017194903A3 FR 2017051165 W FR2017051165 W FR 2017051165W WO 2017194903 A3 WO2017194903 A3 WO 2017194903A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral particle
cells involved
rna transfer
viral rnas
integrase
Prior art date
Application number
PCT/FR2017/051165
Other languages
English (en)
Other versions
WO2017194903A8 (fr
WO2017194903A2 (fr
Inventor
Pascale BOUILLE
Christine DUTHOIT
Lucille LAMOUROUX
Original Assignee
Vectalys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1654333A external-priority patent/FR3051197B1/fr
Priority to JP2018559309A priority Critical patent/JP6916209B2/ja
Priority to CA3023788A priority patent/CA3023788A1/fr
Priority to EP17730842.6A priority patent/EP3454889A2/fr
Priority to CN201780043718.0A priority patent/CN109562150A/zh
Priority to US16/301,354 priority patent/US11371059B2/en
Application filed by Vectalys filed Critical Vectalys
Priority to SG11201810014UA priority patent/SG11201810014UA/en
Priority to AU2017263138A priority patent/AU2017263138B2/en
Publication of WO2017194903A2 publication Critical patent/WO2017194903A2/fr
Publication of WO2017194903A3 publication Critical patent/WO2017194903A3/fr
Priority to IL262944A priority patent/IL262944A/en
Publication of WO2017194903A8 publication Critical patent/WO2017194903A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte à une particule rétrovirale comportant une protéine issue de la polyprotéine Gag, une protéine d'enveloppe, optionnellement une intégrase et au moins deux ARN non viraux encapsidés, les ARN non viraux encapsidés comportant chacun une séquence d'ARN d'intérêt liée à une séquence d'encapsidation, chaque séquence d'encapsidation étant reconnue par un domaine de liaison introduit dans la protéine issue de la polyprotéine Gag et/ou dans l'intégrase, et l'une au moins dédites séquences d'intérêt des ARN non viraux encapsidés comporte une partie codant pour au moins un épitope et/ou au moins une structure moléculaire reconnaissant spécifiquement un épitope.
PCT/FR2017/051165 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune WO2017194903A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2017263138A AU2017263138B2 (en) 2016-05-13 2017-05-12 Viral particle for RNA transfer, especially into cells involved in immune response
CA3023788A CA3023788A1 (fr) 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquees dans la reponse immune
EP17730842.6A EP3454889A2 (fr) 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune
CN201780043718.0A CN109562150A (zh) 2016-05-13 2017-05-12 用于将rna转移到尤其参与免疫应答的细胞中的病毒颗粒
US16/301,354 US11371059B2 (en) 2016-05-13 2017-05-12 Viral particle for the transfer of RNAs, especially into cells involved in immune response
JP2018559309A JP6916209B2 (ja) 2016-05-13 2017-05-12 特に免疫応答に関与する細胞への、ｒｎａの転移のためのウイルス粒子
SG11201810014UA SG11201810014UA (en) 2016-05-13 2017-05-12 Viral particle for rna transfer, especially into cells involved in immune response
IL262944A IL262944A (en) 2016-05-13 2018-11-12 A viral particle for RNA transfer, especially to cells involved in the immune response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1654333A FR3051197B1 (fr) 2016-05-13 2016-05-13 Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune
FR1654333 2016-05-13
FR1752819 2017-03-31
FR1752819 2017-03-31

Publications (3)

Publication Number Publication Date
WO2017194903A2 WO2017194903A2 (fr) 2017-11-16
WO2017194903A3 true WO2017194903A3 (fr) 2018-01-25
WO2017194903A8 WO2017194903A8 (fr) 2018-12-27

Family

ID=59070996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2017/051165 WO2017194903A2 (fr) 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune

Country Status (9)

Country Link
US (1) US11371059B2 (fr)
EP (1) EP3454889A2 (fr)
JP (1) JP6916209B2 (fr)
CN (1) CN109562150A (fr)
AU (1) AU2017263138B2 (fr)
CA (1) CA3023788A1 (fr)
IL (1) IL262944A (fr)
SG (1) SG11201810014UA (fr)
WO (1) WO2017194903A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986051C (fr) * 2015-05-15 2023-09-26 Vectalys Particule retrovirale comportant au moins deux arn non viraux encapsides
US20210129135A1 (en) * 2019-11-01 2021-05-06 Nicholas Crabtree Hourglass shaped blood fractionation tube and system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
JP6212039B2 (ja) 2011-07-27 2017-10-11 ブクタリ 真核細胞の形質導入に有用なウイルスベースのベクター組成物
AU2013207962B2 (en) * 2012-01-12 2017-07-20 Unm Rainforest Innovations Immunogenic HPV L2-containing VLPs and related compositions and methods
WO2016049258A2 (fr) * 2014-09-25 2016-03-31 The Broad Institute Inc. Criblage fonctionnel avec systèmes crisp-cas fonctionnels optimisés

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNE PREL ET AL: "Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 2, 21 October 2015 (2015-10-21), pages 15039, XP055254802, DOI: 10.1038/mtm.2015.39 *
KATHERINE H. CARRUTHERS ET AL: "Fat Grafting as a Vehicle for the Delivery of Recombinant Adenoassociated Viral Vectors to Achieve Gene Modification of Muscle Flaps", ANNALS OF PLASTIC SURGERY., vol. 70, no. 6, 1 June 2013 (2013-06-01), US, pages 726 - 731, XP055353454, ISSN: 0148-7043, DOI: 10.1097/SAP.0b013e3182414add *
MICHAEL R. WILLIAMS ET AL: "A Retroviral CRISPR-Cas9 System for Cellular Autism-Associated Phenotype Discovery in Developing Neurons", SCIENTIFIC REPORTS, vol. 6, 10 May 2016 (2016-05-10), pages 25611, XP055352201, DOI: 10.1038/srep25611 *
PASCALE BOUILLÉ ET AL: "Transient Non-Viral RNA Delivery Mediated by a Lentiviral Particle", MOLECULAR THERAPY, vol. 24, no. S1, 4 May 2016 (2016-05-04), pages S215, XP055354331 *

Also Published As

Publication number Publication date
WO2017194903A8 (fr) 2018-12-27
IL262944A (en) 2018-12-31
AU2017263138B2 (en) 2022-08-25
US20190203228A1 (en) 2019-07-04
JP6916209B2 (ja) 2021-08-11
AU2017263138A1 (en) 2019-01-03
SG11201810014UA (en) 2018-12-28
US11371059B2 (en) 2022-06-28
CN109562150A (zh) 2019-04-02
EP3454889A2 (fr) 2019-03-20
WO2017194903A2 (fr) 2017-11-16
JP2019514413A (ja) 2019-06-06
CA3023788A1 (fr) 2017-11-16

Similar Documents

Publication Publication Date Title
MX2020004578A (es) Composiciones de casz y metodos de uso.
CY1124518T1 (el) Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες
CL2021002741A1 (es) Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de lachnospiraceae bacterium nd2006; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
WO2016196975A8 (fr) Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation
WO2019173692A3 (fr) Anticorps anti-cd73 et leurs procédés d'utilisation
WO2018106615A3 (fr) Compositions et méthodes d'activation d'expression génique
EP3950941A3 (fr) Variants polypeptidiques de la dnase
WO2017178653A3 (fr) Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
WO2017079479A8 (fr) Anticorps neutralisants dirigés contre la protéine gp41 du vih-1 et leur utilisation
JP2017153484A5 (fr)
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
WO2017066764A3 (fr) Modification de la région n-terminale des protéines de capsides pour améliorer les propriétés des virus adéno-associés
WO2016154003A8 (fr) Anticorps neutralisants dirigés contre gp120 et utilisation de ceux-ci
EP4043031A3 (fr) Constructions à base d'antigènes du virus zika
RU2018132044A (ru) Антитела против тау
MX2020012765A (es) Métodos y compuestos de ácido nucleico modificado con lípidos.
EP4339615A3 (fr) Anticorps anti-pd-1
WO2017214462A3 (fr) Anticorps anti-cd98 et conjugués anticorps-médicament
WO2017194902A3 (fr) Particule pour l'encapsidation d'un système d'ingénierie du génome
CA3009928A1 (fr) Vaccin contre le virus de l'encephalite equine base sur un virus modifie de la vaccine ankara (mva) recombinant
WO2012018907A3 (fr) Polypeptides pour traitement et/ou limitation d'infection par la grippe
MX2017008096A (es) Pestivirus.
WO2017152146A3 (fr) Compositions et procédés pour induire des anticorps du vih-1
WO2015112558A3 (fr) Peptides, dispositifs et procédés pour la détection d'anticorps d'anaplasma

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3023788

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018559309

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17730842

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017730842

Country of ref document: EP

Effective date: 20181213

ENP Entry into the national phase

Ref document number: 2017263138

Country of ref document: AU

Date of ref document: 20170512

Kind code of ref document: A